{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-084206","form_type":"8-K","ticker":"GRDX","cik":"0001604191","company_name":"GridAI Technologies Corp.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.735705+00:00","generated_at":"2026-05-31T14:23:22.793215+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Entero Therapeutics provides latiglutenase Phase 3 plan, FDA meetings, $1.9M raise","bullets":["Submits Type D requests to FDA to streamline Phase 3 trial cohorts from three to two (1200 mg and placebo).","Second Type D request seeks FDA agreement on histology secondary endpoints based on Phase 2 results.","Raised $1.9 million in gross proceeds from a small financing to support Phase 3 trial initiation.","Consolidated bi-coastal operations into Boca Raton HQ to reduce overhead costs.","CEO James Sapirstein reaffirms goal to start pivotal Phase 3 trial for latiglutenase in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-084206","json":"https://secwatch.observer/filing/0001104659-24-084206.json","markdown":"https://secwatch.observer/filing/0001104659-24-084206.md","text":"https://secwatch.observer/filing/0001104659-24-084206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924084206/0001104659-24-084206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604191/000110465924084206/tm2420546d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:23:22.793215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}